Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
This open-label, randomized, active-controlled phase 3 trial enrolled 2,002 adults with type 2 diabetes and elevated cardiovascular risk, comparing tirzepatide with titrated insulin glargine over a 52-week treatment period
Consultation with a cardiologist may be appropriate for patients with complex cardiac histories
Weight loss itself can cause transient transaminase elevations as hepatic fat mobilizes, a phenomenon well-documented in bariatric surgery literature and now recognized in pharmacologic weight-loss settings
Most people who experience it notice increased shedding around months 4-6 of treatment
US$ 23.38
US$ 26.00
US$ 22.32
US$ 27.54
US$ 24.28
US$ 21.74
